SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers
- A global licensing agreement has been signed for the development and […]
Focus on FAPI Newsletter – Summer 2023
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Dear FAPI community,
It was a busy and exciting summer.
In […]
Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study GalleryHead-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study
Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study
Emil Novruzov1, Frederik L Giesel1,2, Yuriko Mori1, Peter L Choyke3, Mardjan Dabir1, Eduards Mamlins1, Dominik […]
Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib GalleryComparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib
Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib
Meiqi Wu1, Yanyu Wang2, Qiao Yang1, Xuezhu Wang1, Xu Yang2, Haiqun Xing1, Xinting Sang2, Xiang […]
Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis GalleryDiagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis
Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis
Alessio Rizzo1, Manuela Racca1, Federico Garrou2, Elisabetta Fenocchio3, Luca Pellegrino4, Domenico Albano5, Francesco Dondi5, Francesco […]
FAP symposium another success at 2023 SNMMI meeting
June 25, 2023 – For the second year in a row, the spotlight shone on […]
RLS and SOFIE Enter Strategic Partnership for Distribution of Nuclear Medicine Doses for Patients
LAKE ZURICH, Il. and DULLES, Va. — June 21, 2023, RLS (USA), […]
Focus on FAPI Newsletter – Spring 2023
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Dear FAPI community,
This quarter, the FAPI team celebrated […]
SOFIE partners with BAMF Health, diversifying sites for Phase II [68Ga]FAPI-46 study
SOFIE has added BAMF Health, a novel cancer treatment center in Grand Rapids, Michigan, as […]
First Patient Imaged in SOFIE’s 18F-FAPI Phase 2 trial
Dulles, VA –May 12, 2023 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]